Clinicopathological Characteristics and Survival Analysis of 87 Male Breast Cancer Cases

Liu, Tingting; Tong, Zhongsheng; He, Lihong; Zhang, Li

doi:10.1159/000335204

Cited by 14 publications

(17 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These rates are comparable to the results presented in the literature, which are as follows: 41-75% for 5-year (OS) and 60-73% (DFS) [20,21,25,28,31,34].…”

Section: Discussionsupporting

confidence: 90%

“…It was indicated that the most important prognostic factor for male breast cancer patients is the presence of metastases in the lymph nodes [21,27,31,34]. Our observations are similar.…”

Section: Discussionsupporting

confidence: 87%

“…In the literature the size of the analysed groups ranges from 31 to 118 patients, studied over a periods from 14 to 47 years [15,16,20,21,27,28,29,31,33]. The number of male patients treated for breast carcinoma at the Institute of Oncology in Cracow is similar.…”

Section: Discussionmentioning

confidence: 99%

“…There are also differences in the frequency of the expression of hormone receptors and growth factor receptors [19,20]. Besides, the prognosis for male breast cancer is worse [5,18,20,21]. A study by Baojiang et al of 5-year survival rates of patients suffering from male breast carcinoma and female breast carcinoma produced the following results: 61.2% and 68.7% (DFS), and 75.% and 82.9% (OS), respectively [20].…”

mentioning

confidence: 99%

“…The treatment of male breast carcinoma is based on standard methods, more specifically surgical procedures [6,21,25,26]. Breast amputations are more frequent in male patients than in female [6,15,17,26].…”

mentioning

confidence: 99%

See 4 more Smart Citations

The biological markers and results of treatment in male breast cancer patients. The Cracow experience.

Sas-Korczyńska¹,

Niemiec²,

Harazin-Lechowska³

et al. 2014

neo

View full text Add to dashboard Cite

Male breast cancer is a rare form of carcinoma with an incidence rate of approximately 0.5-1% compared with cases of breast carcinoma as a whole. Male breast cancer reacts effectively to endocrine therapy because of a high frequency of hormone receptor expression.The aim of the present study was the assessment of correlations between stage, grade, expression of steroid receptors, basal/mesenchymal markers and proliferation index, as well as analysis of the impact of the above-mentioned parameters on overall (OS) and disease-free survival (DFS) in the group of 32 male breast cancer patients, treated at the Centre of Oncology in Cracow.We showed the significant positive correlation between MIB-1 LI and tumor stage, and hormone receptors (ER or PgR) immunonegativity, and expression of EGFR, vimentin (p<0.05) and P-cadherin (the last at statistical border). The presence of any of basal or masenchymal markers correlated with a more advanced tumor stage. Moreover tumors without vimentin expression were characterised by lower MIB-1 LI and were more frequently EGFR immunonegative.We found that hormone receptor negativity, vimentin immunopositivity and high MIB-1 LI are significant independent indicators of poor OS and DFS for male breast cancer patients (p<0.05). Key words: male breast cancer, basal markers, mesenchymal markers, nodal status, hormonal receptorsMale breast cancer is a rare form of carcinoma with an incidence rate of approximately 0.5-1% compared with cases of breast carcinoma as a whole [1,2,3,4]. Its peak incidence is noted in the seventh decade of life [5,6,7]. The most significant risk factors are an increased concentration of estrogen and obesity, that are a result of estrogen overproduction, impaired metabolism, and disturbances in the concentration of estrogen and androgen (i.e. in Klinefelter's syndrome) as well as the use of estrogenes in prostate cancer treatment [6,8,9,10,11]. Other factors include alcoholism, liver cirrhosis, the presence of hereditary BRCA1 and BRCA2 gene mutations and exposure to ionizing radiation, the electromagnetic field and increased temperature [6,8,9,12,13,14,15,16,17].According to Anderson et al., male breast cancer is characterised by similar biological factors to those present in the female variant of the cancer [18]. However, these tumors are diagnosed in more advanced stages of the disease, are characterised by higher degree of differentiation (more frequently G1, G2 grade) and a lower mitotic index in comparison to female breast cancer [5,19]. There are also differences in the frequency of the expression of hormone receptors and growth factor receptors [19,20]. Besides, the prognosis for male breast cancer is worse [5,18,20,21]. A study by Baojiang et al. of 5-year survival rates of patients suffering from male breast carcinoma and female breast carcinoma produced the following results: 61.2% and 68.7% (DFS), and 75.% and 82.9% (OS), respectively [20].Male breast cancer has a higher (over 90%) hormone receptor expression and, as a consequence, reacts more effect...

show abstract

“…These rates are comparable to the results presented in the literature, which are as follows: 41-75% for 5-year (OS) and 60-73% (DFS) [20,21,25,28,31,34].…”

Section: Discussionsupporting

confidence: 90%

“…It was indicated that the most important prognostic factor for male breast cancer patients is the presence of metastases in the lymph nodes [21,27,31,34]. Our observations are similar.…”

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

The biological markers and results of treatment in male breast cancer patients. The Cracow experience.

Sas-Korczyńska¹,

Niemiec²,

Harazin-Lechowska³

et al. 2014

neo

View full text Add to dashboard Cite

show abstract

Patterns of recurrence and treatment in male breast cancer: A clue to prognosis?

Abreu

Afonso

et al. 2016

Intl Journal of Cancer

View full text Add to dashboard Cite

Male breast cancer (MBC) patients seem to have inferior survival compared to female (FBC) ones, which is not fully explained by usual prognostic factors. Recurrence analysis could show differences in relapse patterns and/or in patients' approaches that justify these outcomes. Retrospective analysis of MBC patients treated in a cancer center between 1990 and 2014, looking for relapse. For each patient, three matched FBC patients were selected by: diagnosis' year, age (within 5 years), stage and tumors' type (only luminal-like were considered). Differences between cohorts were assessed by χ(2) test and hierarchical clustering was performed to define subgroups according to relapse local. Survival curves were calculated by Kaplan-Meier and compared using log-rank test. Statistical significance was defined as p < 0.05. Groups were balanced according to age, histological grade, stage, expression of hormonal receptors and adjuvant treatments. Median time to recurrence was equivalent, p = 0.72, with the majority of patients presented with distant metastases, p = 0.69, with more lung involvement in male, p = 0.003. Male patients were more often proposed to symptomatic treatment (21.1% vs. 4.4%, p = 0.02). Overall and from recurrence survivals were poorer for male, median: 5 years [95% confidence interval (CI): 4.1-5.9 years] and 1 year (95% CI: 0-2.1 years) vs. 10 years (95% CI: 7.8-12.2 years) and 2 years (95% CI: 1.6-2.4 years), p < 0.001 and p = 0.004, respectively, and this tendency remained in the five cluster subgroups, that identified five patterns of relapse, p = 0.003. MBC patients had the worst survival, even after controlling important factors, namely the local of relapse. Palliative systemic treatment had favorable impact in prognosis and its frequently avoidance in male could justify the outcomes differences.

show abstract

The Problem

Fentiman¹

2017

Male Breast Cancer

View full text Add to dashboard Cite

Clinicopathological Characteristics and Survival Analysis of 87 Male Breast Cancer Cases

Cited by 14 publications

References 30 publications

The biological markers and results of treatment in male breast cancer patients. The Cracow experience.

The biological markers and results of treatment in male breast cancer patients. The Cracow experience.

Patterns of recurrence and treatment in male breast cancer: A clue to prognosis?

The Problem

Contact Info

Product

Resources

About